Asia-Pacific Cancer Diagnostics Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Asia-Pacific Cancer Diagnostics Market Size

• The Asia-Pacific cancer diagnostics market size was valued at USD 22.20 billion in 2025 and is expected to reach USD 39.59 billion by 2033, at a CAGR of 7.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of cancer worldwide and the growing demand for early detection technologies, leading to higher adoption of advanced diagnostic tools in both hospitals and specialized laboratories
• Furthermore, rising investments in precision medicine, biomarker-based testing, and technological advancements in imaging and molecular diagnostics are establishing cancer diagnostics as a critical component of modern healthcare. These converging factors are accelerating the uptake of Cancer Diagnostics solutions, thereby significantly boosting the industry's growth

Asia-Pacific Cancer Diagnostics Market Analysis

• Cancer diagnostics, offering advanced technologies for early detection, screening, and monitoring of cancer, are increasingly vital components of modern healthcare systems in both hospitals and diagnostic laboratories due to their ability to improve treatment outcomes and patient survival rates
• The escalating demand for cancer diagnostics is primarily fueled by the rising global cancer burden, growing awareness about early detection, and increasing adoption of advanced technologies such as molecular diagnostics, imaging, and biomarker-based testing
• China dominated the cancer diagnostics market with the largest revenue share of 36.8% in 2025, characterized by expanding healthcare infrastructure, rising cancer screening initiatives, and increasing investments in diagnostic technologies, with strong growth driven by government healthcare programs and the presence of major diagnostic equipment manufacturers
• India is expected to be the fastest growing region in the cancer diagnostics market during the forecast period with a projected CAGR of 10.4%, due to increasing healthcare expenditure, improving diagnostic infrastructure, and growing awareness regarding early cancer detection
• The Instrument Based segment dominated the largest market revenue share of 45.3% in 2025, supported by the extensive use of diagnostic instruments such as imaging systems, sequencing machines, and pathology analyzers

Report Scope and Cancer Diagnostics Market Segmentation

Asia-Pacific Cancer Diagnostics Market Trends

Rising Adoption of Advanced Diagnostic Technologies for Early Cancer Detection

• A significant and accelerating trend in the global cancer diagnostics market is the growing adoption of advanced diagnostic technologies aimed at improving early cancer detection and treatment outcomes. Healthcare providers across the world are increasingly utilizing innovative diagnostic tools such as molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy to identify cancer at earlier stages, enabling more effective and personalized treatment strategies
  • For instance, several healthcare institutions and diagnostic laboratories are increasingly implementing liquid biopsy tests that allow the detection of circulating tumor DNA in blood samples. These tests provide a minimally invasive method for identifying cancer biomarkers, monitoring treatment responses, and detecting cancer recurrence, thereby improving patient management and clinical outcomes
• The increasing awareness about the importance of early cancer screening programs is also contributing significantly to the expansion of cancer diagnostic technologies. Governments and healthcare organizations across multiple regions are promoting large-scale screening initiatives for cancers such as breast cancer, colorectal cancer, and cervical cancer, which is increasing demand for reliable diagnostic solutions
• Furthermore, technological advancements in imaging systems and molecular testing platforms are enabling healthcare professionals to detect tumors with greater accuracy and speed. The integration of advanced diagnostic instruments within hospitals, research laboratories, and specialized cancer centers is strengthening the diagnostic infrastructure globally
• The growing focus on personalized medicine is also encouraging the use of biomarker-based diagnostic testing to guide treatment decisions. By identifying specific genetic mutations associated with cancer, clinicians can select targeted therapies that improve treatment effectiveness and reduce unnecessary side effects
• As healthcare systems worldwide continue to prioritize early detection and precision oncology, the demand for advanced cancer diagnostic tools and technologies is expected to increase significantly during the forecast period

Asia-Pacific Cancer Diagnostics Market Dynamics

Driver

Increasing Global Cancer Incidence and Expanding Healthcare Infrastructure

• The rising global incidence of cancer is a major factor driving the growth of the Cancer Diagnostics market. According to global health organizations, the number of cancer cases continues to increase due to factors such as aging populations, lifestyle changes, and environmental risk factors, which is significantly increasing the demand for early and accurate diagnostic solutions
  • For instance, governments and healthcare organizations across regions such as North America, Europe, and Asia-Pacific are investing heavily in nationwide cancer screening initiatives to improve early detection rates. These programs encourage individuals to undergo routine diagnostic tests, thereby increasing demand for diagnostic equipment and laboratory services
• The expansion of healthcare infrastructure, particularly in emerging economies, is further supporting market growth. The development of modern hospitals, specialized cancer treatment centers, and diagnostic laboratories is increasing access to advanced diagnostic technologies
• In addition, the continuous growth of the biotechnology and pharmaceutical industries is contributing to increased research and development activities related to cancer biomarkers and molecular diagnostics. This is leading to the introduction of more sophisticated diagnostic platforms capable of detecting cancer with higher sensitivity and accuracy
• The growing adoption of personalized medicine and targeted therapies is also increasing the importance of diagnostic testing in oncology. Physicians rely on detailed diagnostic data to determine the most appropriate treatment strategy for individual patients
• Furthermore, increasing public awareness regarding the importance of early cancer diagnosis, supported by healthcare campaigns and educational initiatives, is encouraging individuals to undergo preventive screening and diagnostic tests

Restraint/Challenge

High Diagnostic Costs and Limited Access in Developing Regions

• Despite significant advancements in diagnostic technologies, the high cost associated with advanced cancer diagnostic tests remains a major challenge for the global market. Technologies such as next-generation sequencing and molecular biomarker testing often require sophisticated equipment and specialized laboratory expertise, which can increase overall diagnostic expenses
  • For instance, in several developing countries, access to advanced molecular diagnostic testing remains limited due to high equipment costs and insufficient laboratory infrastructure, which can delay early cancer detection and treatment
• Limited healthcare infrastructure in certain regions also restricts the availability of advanced diagnostic facilities. Many rural or underserved areas lack specialized laboratories and trained healthcare professionals required to perform complex diagnostic procedures
• In addition, regulatory requirements for diagnostic devices and testing procedures can be rigorous and time-consuming, which may delay the commercialization and adoption of new diagnostic technologies
• Another challenge is the shortage of skilled professionals capable of interpreting complex diagnostic data, particularly in emerging healthcare markets where specialized oncology expertise may be limited
• Addressing these challenges through improved healthcare funding, expansion of diagnostic infrastructure, training programs for healthcare professionals, and the development of cost-effective diagnostic technologies will be essential for ensuring the sustained growth of the global Cancer Diagnostics market

Asia-Pacific Cancer Diagnostics Market Scope

The market is segmented on the basis of type, technology, application, and end user.

• By Type

On the basis of type, the Cancer Diagnostics market is segmented into Laboratory Tests, Genetic Tests, Tumor Biomarkers Tests, Imaging, Endoscopy, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, and Others. The Imaging segment dominated the largest market revenue share of 27.8% in 2025, driven by its critical role in early cancer detection, diagnosis, and treatment monitoring. Imaging technologies such as CT scans, MRI, PET scans, and mammography are widely used in hospitals and diagnostic centers for detecting tumors and assessing disease progression. Healthcare providers rely heavily on imaging diagnostics because they provide detailed visualization of internal organs and tissues. The rising prevalence of cancer worldwide has significantly increased the demand for advanced imaging technologies. Hospitals and diagnostic laboratories continuously invest in high-resolution imaging systems to improve diagnostic accuracy. Imaging methods are non-invasive and allow physicians to detect cancer at early stages, improving patient survival rates. The increasing adoption of AI-powered imaging analysis tools is further enhancing diagnostic efficiency. Growing healthcare infrastructure in emerging markets also supports the expansion of imaging diagnostic services. Government screening programs for cancers such as breast and lung cancer further boost demand. Technological advancements such as 3D imaging and hybrid imaging systems continue to strengthen this segment’s dominance.

The Liquid Biopsy segment is expected to witness the fastest CAGR of 9.2% from 2026 to 2033, driven by the increasing demand for minimally invasive cancer diagnostic techniques. Liquid biopsy enables the detection of circulating tumor DNA (ctDNA) and cancer-related biomarkers from blood samples. This technology allows physicians to monitor tumor progression and treatment response without requiring invasive surgical procedures. Hospitals and diagnostic laboratories are increasingly adopting liquid biopsy due to its convenience and reduced patient discomfort. The growing focus on precision medicine and personalized cancer treatment is also accelerating the use of liquid biopsy tests. Pharmaceutical companies use liquid biopsy for monitoring therapeutic outcomes and clinical trials. Advances in genomic technologies and biomarker discovery are improving the sensitivity and accuracy of these tests. Increasing investments in oncology research and biotechnology innovations further support market growth. Liquid biopsy is particularly useful in detecting cancer recurrence and monitoring metastasis. As demand for early detection and personalized medicine grows, liquid biopsy technologies are expected to experience rapid adoption worldwide.

• By Technology

On the basis of technology, the Cancer Diagnostics market is segmented into Instrument Based, Platform-Based, and Tumor Biomarker Tests. The Instrument Based segment dominated the largest market revenue share of 45.3% in 2025, supported by the extensive use of diagnostic instruments such as imaging systems, sequencing machines, and pathology analyzers. Hospitals and diagnostic laboratories rely heavily on instrument-based technologies for accurate cancer detection and disease staging. These instruments provide highly precise diagnostic results and enable clinicians to identify tumors at early stages. Technological advancements such as digital pathology systems and automated diagnostic equipment have further enhanced diagnostic accuracy. Healthcare institutions are continuously investing in advanced diagnostic instruments to improve efficiency and reduce turnaround time for test results. Increasing cancer screening programs worldwide are also contributing to the demand for instrument-based diagnostics. Integration of artificial intelligence with diagnostic instruments is further improving data interpretation and clinical decision-making. Pharmaceutical companies and research institutes also utilize these instruments for oncology research and drug development. Growing healthcare spending and technological innovation continue to support this segment’s dominance.

The Tumor Biomarker Tests segment is expected to witness the fastest CAGR of 8.7% from 2026 to 2033, driven by the increasing focus on personalized medicine and targeted cancer therapies. Tumor biomarkers help identify specific genetic mutations and molecular characteristics of tumors. Physicians use these tests to select the most effective treatment options for individual patients. Advances in molecular biology and genomics have significantly improved biomarker discovery and testing methods. Pharmaceutical companies rely on biomarker testing to develop targeted cancer therapies and companion diagnostics. Diagnostic laboratories are expanding biomarker testing services to support personalized oncology treatments. The growing adoption of precision medicine is further increasing the demand for biomarker-based diagnostics. Biomarker tests are widely used for monitoring disease progression and predicting treatment response. Increased investments in oncology research and biotechnology innovations are accelerating this segment’s growth. As healthcare systems focus more on individualized treatment approaches, tumor biomarker tests are expected to play a crucial role in cancer diagnostics.

• By Application

On the basis of application, the Cancer Diagnostics market is segmented into Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Pancreatic Cancer, Ovarian Cancer, and Others. The Breast Cancer segment dominated the largest market revenue share of 21.6% in 2025, primarily due to the high global prevalence of breast cancer and the widespread implementation of screening programs. Diagnostic techniques such as mammography, biopsy, and genetic testing are widely used for early detection and diagnosis. Governments and healthcare organizations actively promote breast cancer screening programs to improve early detection rates. Hospitals and diagnostic laboratories frequently conduct imaging and biomarker tests for breast cancer diagnosis. The increasing availability of advanced imaging technologies further enhances diagnostic accuracy. Rising awareness among women about early detection also contributes to growing demand for diagnostic tests. Pharmaceutical companies and research institutions are investing in improved diagnostic technologies for breast cancer detection. Early diagnosis significantly increases survival rates, encouraging routine screening practices. As breast cancer remains one of the most commonly diagnosed cancers worldwide, diagnostic demand continues to grow steadily.

The Lung Cancer segment is expected to witness the fastest CAGR of 8.9% from 2026 to 2033, driven by the rising prevalence of lung cancer and increasing adoption of advanced diagnostic technologies. Lung cancer is one of the leading causes of cancer-related deaths globally, which has intensified the focus on early detection. Diagnostic methods such as CT scans, molecular testing, and liquid biopsy are increasingly used for identifying lung tumors. Healthcare providers are implementing low-dose CT screening programs to detect lung cancer at earlier stages. The growing prevalence of smoking and environmental pollution further increases the need for effective diagnostic solutions. Advances in genomic testing are also improving the accuracy of lung cancer diagnosis. Pharmaceutical companies rely on molecular diagnostics to develop targeted therapies for lung cancer. Increasing awareness and screening initiatives are further supporting diagnostic adoption. As research continues to improve detection technologies, the lung cancer diagnostic segment is expected to grow rapidly in the coming years.

• By End User

On the basis of end user, the Cancer Diagnostics market is segmented into Cancer Research Institutes, Diagnostic Laboratories, Hospitals, and Others. The Hospitals segment dominated the largest market revenue share of 48.2% in 2025, driven by the high volume of cancer diagnostic procedures performed in hospital settings. Hospitals possess advanced diagnostic equipment and specialized oncology departments capable of conducting complex diagnostic tests. Patients often visit hospitals for comprehensive cancer screening, diagnosis, and treatment planning. Hospitals also serve as major centers for imaging diagnostics, biopsy procedures, and molecular testing. The presence of multidisciplinary medical teams ensures accurate diagnosis and integrated cancer care. Increasing patient admissions and rising cancer prevalence further contribute to higher diagnostic volumes in hospitals. Government healthcare programs and insurance coverage often support hospital-based cancer diagnostics. Hospitals also participate in clinical trials and oncology research programs. Continuous investments in advanced diagnostic infrastructure further strengthen this segment’s dominance.

The Diagnostic Laboratories segment is expected to witness the fastest CAGR of 8.5% from 2026 to 2033, driven by the increasing demand for specialized cancer testing services. Diagnostic laboratories offer advanced molecular diagnostics, genetic testing, and biomarker analysis. Many hospitals and clinics outsource complex diagnostic tests to specialized laboratories to improve efficiency. Technological advancements in genomic sequencing and molecular diagnostics are further supporting the growth of laboratory testing services. The expansion of private diagnostic laboratory chains is increasing accessibility to advanced cancer tests. Home sample collection services and telemedicine integration are also improving patient convenience. Diagnostic laboratories play a crucial role in early cancer detection and personalized treatment planning. Growing investments in biotechnology and diagnostic research are further driving innovation. As demand for precise and rapid cancer diagnostics continues to grow, diagnostic laboratories are expected to become key contributors to market expansion.

Asia-Pacific Cancer Diagnostics Market Regional Analysis

• The Asia-Pacific cancer diagnostics market is projected to expand at a substantial CAGR during the forecast period, primarily driven by the rising incidence of cancer, increasing healthcare investments, and the growing emphasis on early disease detection across the region. Governments and healthcare organizations are actively promoting cancer screening programs and expanding diagnostic infrastructure to improve early diagnosis and treatment outcomes
• In addition, the rapid development of hospitals, diagnostic laboratories, and specialized cancer centers across countries such as China, India, Japan, and South Korea is significantly strengthening the availability of advanced diagnostic technologies. Technological advancements in molecular diagnostics, imaging technologies, and biomarker testing are further improving diagnostic accuracy and enabling more effective cancer management
• Moreover, increasing public awareness regarding preventive healthcare and early cancer screening is encouraging individuals to undergo routine diagnostic testing, thereby supporting the growth of the cancer diagnostics market across the Asia-Pacific region

China Cancer Diagnostics Market Insight

The China cancer diagnostics market dominated the Asia-Pacific market with the largest revenue share of 36.8% in 2025, supported by the country’s rapidly expanding healthcare infrastructure and increasing government initiatives aimed at improving cancer detection and treatment. China has significantly increased its investments in healthcare facilities, diagnostic laboratories, and cancer research centers, enabling wider access to advanced diagnostic technologies. Large-scale national cancer screening programs and public health campaigns have also contributed to increasing awareness regarding early diagnosis and preventive healthcare. Additionally, the presence of major diagnostic equipment manufacturers and the continuous development of innovative diagnostic technologies are strengthening China’s leadership in the regional cancer diagnostics market.

India Cancer Diagnostics Market Insight

The India cancer diagnostics market is expected to grow at the fastest CAGR of 10.4% during the forecast period, driven by increasing healthcare expenditure, expanding diagnostic infrastructure, and rising awareness regarding early cancer detection. The country is witnessing rapid growth in the number of diagnostic laboratories, cancer treatment centers, and specialized hospitals that offer advanced diagnostic services. Government initiatives aimed at improving healthcare accessibility and promoting cancer screening programs are also playing an important role in expanding the diagnostic landscape. Furthermore, the growing adoption of modern diagnostic technologies, along with increasing investments by private healthcare providers, is contributing to improved availability of cancer diagnostic services across both urban and semi-urban regions of India.

Asia-Pacific Cancer Diagnostics Market Share

The Cancer Diagnostics industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Siemens Healthineers AG (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Agilent Technologies, Inc. (U.S.)
• Danaher Corporation (U.S.)
• Hologic, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Myriad Genetics, Inc. (U.S.)
• PerkinElmer, Inc. (U.S.)
• Guardant Health, Inc. (U.S.)
• Exact Sciences Corporation (U.S.)
• Foundation Medicine, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Fujifilm Holdings Corporation (Japan)
• Mindray Medical International Limited (China)
• BGI Genomics Co., Ltd. (China)

Latest Developments in Asia-Pacific Cancer Diagnostics Market

• In June 2021, GRAIL, a biotechnology company focused on early cancer detection, announced the commercial launch of the Galleri multi-cancer early detection blood test, designed to detect signals from more than 50 types of cancer using a single blood sample. The test analyzes DNA methylation patterns in circulating tumor DNA to identify the presence of cancer and predict its tissue of origin. This launch marked a significant milestone in the development of liquid biopsy technologies and highlighted the growing adoption of non-invasive cancer diagnostics for early detection
• In May 2022, Guardant Health introduced the Shield blood-based screening test for colorectal cancer, designed as a minimally invasive alternative to traditional screening methods such as colonoscopy. The liquid biopsy test demonstrated approximately 83% sensitivity for detecting colorectal cancer in clinical studies, expanding the use of blood-based diagnostic technologies for early cancer detection
• In October 2024, the U.S. Food and Drug Administration approved FoundationOne Liquid CDx as a companion diagnostic test to identify patients with hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation who may benefit from targeted therapy such as inavolisib. The approval strengthened the role of genomic profiling and companion diagnostics in precision oncology
• In April 2025, Molbio Diagnostics launched India’s first indigenously developed HPV molecular diagnostic test kits for cervical cancer screening on its Truenat platform. The test kits were validated by the All India Institute of Medical Sciences (AIIMS) and the International Agency for Research on Cancer, enabling faster and more accessible cervical cancer diagnostics in resource-limited settings

SKU-12062